Cargando…

Herd Immunity to Ebolaviruses Is Not a Realistic Target for Current Vaccination Strategies

The recent West African Ebola virus pandemic, which affected >28,000 individuals increased interest in anti-Ebolavirus vaccination programs. Here, we systematically analyzed the requirements for a prophylactic vaccination program based on the basic reproductive number (R(0), i.e., the number of s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masterson, Stuart G., Lobel, Leslie, Carroll, Miles W., Wass, Mark N., Michaelis, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954026/ https://www.ncbi.nlm.nih.gov/pubmed/29867992 http://dx.doi.org/10.3389/fimmu.2018.01025

Ejemplares similares

Risks Posed by Reston, the Forgotten Ebolavirus
por: Cantoni, Diego, et al.
Publicado: (2016)

Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection
por: Longet, Stephanie, et al.
Publicado: (2021)

Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses
por: Pappalardo, Morena, et al.
Publicado: (2016)

The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
por: Frederiksen, Lea Skak Filtenborg, et al.
Publicado: (2020)

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development
por: Murin, Charles D., et al.
Publicado: (2022)

Ebolavirus: Infection, Vaccination and Control
por: Ahad, Abdul, et al.
Publicado: (2022)

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species
por: Hensley, Lisa E., et al.
Publicado: (2010)

Ebolavirus Database: Gene and Protein Information Resource for Ebolaviruses
por: Swetha, Rayapadi G., et al.
Publicado: (2016)

Challenges of vaccination and herd immunity in COVID‐19 and management strategies
por: She, Jun, et al.
Publicado: (2022)

Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus
por: Wolfe, Daniel N., et al.
Publicado: (2020)

Is Herd Immunity Against SARS-CoV-2 a Silver Lining?
por: Vignesh, Ramachandran, et al.
Publicado: (2020)

Ebolavirus in West Africa, and the use of experimental therapies or vaccines
por: Hoenen, Thomas, et al.
Publicado: (2014)

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a Pan-Ebolavirus Immunotherapeutic
por: Kuang, Erin, et al.
Publicado: (2022)

Assembly and Budding of Ebolavirus
por: Noda, Takeshi, et al.
Publicado: (2006)

Ebolavirus comparative genomics
por: Jun, Se-Ran, et al.
Publicado: (2015)

Ebolavirus and Other Filoviruses
por: Leroy, E., et al.
Publicado: (2007)

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma
por: Gilchuk, Pavlo, et al.
Publicado: (2021)

Development of Dog Vaccination Strategies to Maintain Herd Immunity against Rabies
por: Lugelo, Ahmed, et al.
Publicado: (2022)

Dendritic Cells Generated From Mops condylurus, a Likely Filovirus Reservoir Host, Are Susceptible to and Activated by Zaire Ebolavirus Infection
por: Edenborough, Kathryn M., et al.
Publicado: (2019)

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
por: Gilchuk, Pavlo, et al.
Publicado: (2018)

Accounting for population structure reveals ambiguity in the Zaire Ebolavirus reservoir dynamics
por: Vrancken, Bram, et al.
Publicado: (2020)

COVID-19, Herd Immunity and Vaccine
por: Tin, Sim Sai, et al.
Publicado: (2023)

Herd immunity, vaccination and moral obligation
por: Bullen, Matthew, et al.
Publicado: (2023)

Strategies to Improve Vaccine Efficacy against Tuberculosis by Targeting Innate Immunity
por: Schaible, Ulrich E., et al.
Publicado: (2017)

The herd-immunity threshold must be updated for multi-vaccine strategies and multiple variants
por: Yadegari, Iraj, et al.
Publicado: (2021)

Network models to evaluate vaccine strategies towards herd immunity in COVID-19
por: Tetteh, Josephine N.A., et al.
Publicado: (2021)

Sudan ebolavirus long recovered survivors produce GP-specific Abs that are of the IgG1 subclass and preferentially bind FcγRI
por: Radinsky, Olga, et al.
Publicado: (2017)

Herd Immunity to Fight Against COVID-19: A Narrative Review
por: Suryawanshi, Yasha N, et al.
Publicado: (2023)

Ebolavirus Evolution: Past and Present
por: de La Vega, Marc-Antoine, et al.
Publicado: (2015)

Virological diagnosis of Ebolavirus infection
por: Smith, D. W., et al.
Publicado: (2015)

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines
por: Coller, Beth-Ann G., et al.
Publicado: (2022)

Vaccine herd effect
por: Kim, Tae Hyong, et al.
Publicado: (2011)

Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics
por: Mellors, Jack, et al.
Publicado: (2020)

Herd immunity and vaccination of children for COVID-19
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2020)

Vaccination Is the Only Acceptable Path to Herd Immunity
por: Rasmussen, Angela L.
Publicado: (2020)

Vaccination and herd immunity thresholds in heterogeneous populations
por: Elbasha, Elamin H., et al.
Publicado: (2021)

The effect of herd immunity thresholds on willingness to vaccinate
por: Andersson, Per A., et al.
Publicado: (2022)

Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system
por: Strzelec, Martyna, et al.
Publicado: (2023)

Iceland targets herd immunity
por: Wilson, Clare
Publicado: (2022)

Structural Basis for Differential Neutralization of Ebolaviruses
por: Bale, Shridhar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_37mocuatf0raohfd8pkp5gle6r